Associated Papers
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Park JJ et al.
Clinical Genitourinary Cancer, 2026
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.
Tsukahara S et al.
Cancer Medicine, 2025
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Zengin ZB et al.
Prostate Cancer and Prostatic Diseases, 2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population.
Arun AS et al.
The Pharmacogenomics Journal, 2025
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
Dorff T et al.
Research Square, 2023
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.
Bang S et al.
Cancers, 2023
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.
Snaterse G et al.
Prostate Cancer and Prostatic Diseases, 2023
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
Doamekpor SK et al.
Acta Crystallographica. Section F, Structural Biology Communications, 2023
A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Béraud C et al.
Frontiers in Oncology, 2023
Simulating androgen receptor selection in designer yeast.
Zhang H et al.
Synthetic and Systems Biotechnology, 2022
Yeast-based evolutionary modeling of androgen receptor mutations and natural selection.
Zhang H et al.
Plos Genetics, 2022
Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M et al.
Endocrine-related Cancer, 2022
Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.
Radaeva M et al.
Cells, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Herberts C et al.
Nature, 2022
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
Palicelli A et al.
Biomedicines, 2022
Clinical, Biochemical, and Molecular Characterization of Indian Children with Clinically Suspected Androgen Insensitivity Syndrome.
Kumar A et al.
Sexual Development : Genetics, Molecular Biology, Evolution, Endocrinology, Embryology, and Pathology of Sex Determination and Differentiation, 2022
Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
Lieb V et al.
Cells, 2021
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
Jacob A et al.
Cancers, 2021
Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients.
Lallous N et al.
Cancers, 2021
Clinical implications of genomic alterations in metastatic prostate cancer.
Sumiyoshi T et al.
Prostate Cancer and Prostatic Diseases, 2021
Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer.
Branch JR et al.
Molecular Cancer Therapeutics, 2021
Characterization of Clonal Evolution in Microsatellite Unstable Metastatic Cancers through Multiregional Tumor Sequencing.
Bonneville R et al.
Molecular Cancer Research : Mcr, 2021
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H et al.
European Urology, 2020
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM et al.
The Oncologist, 2020
Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer.
Moses M et al.
Oncotarget, 2020
Towards precision oncology in advanced prostate cancer.
Ku SY et al.
Nature Reviews. Urology, 2019
Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models.
Sugawara T et al.
International Journal of Cancer, 2019
Identification of single nucleotide variants using position-specific error estimation in deep sequencing data.
Kleftogiannis D et al.
Bmc Medical Genomics, 2019
Detecting predictive androgen receptor modifications in circulating prostate cancer cells.
Steinestel J et al.
Oncotarget, 2019
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T et al.
Scientific Reports, 2019
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Annala M et al.
Cancer Discovery, 2018
Clinical relevance of androgen receptor alterations in prostate cancer.
Jernberg E et al.
Endocrine Connections, 2017
Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.
Dalal K et al.
Molecular Cancer Therapeutics, 2017
An original patient-derived xenograft of prostate cancer with cyst formation.
Yoshikawa T et al.
The Prostate, 2016
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide.
Prekovic S et al.
Molecular Cancer Therapeutics, 2016
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N et al.
Genome Biology, 2016
Plasma AR and abiraterone-resistant prostate cancer.
Romanel A et al.
Science Translational Medicine, 2015
Integrative clinical genomics of advanced prostate cancer.
Robinson D et al.
Cell, 2015